Helen of Troy Limited (HELE) Balance Sheet

The asset base has shrunk in every quarter since the 2025Q4 peak, but the composition of that decline matters more than the headline number. Goodwill fell from $1.2B to $472.3M across the period—reflecting the large non-cash impairments already identified in prior income statement analysis—while total debt was simultaneously reduced from $956.8M to $672.6M. This dual contraction suggests the company is simultaneously absorbing past acquisition excesses and tightening its capital structure. Equity, which bottomed at $798.2M in 2026Q4, has since recovered to $1.4B, though the source of that recovery (whether operating earnings or a capital raise) is not fully transparent from balance sheet data alone and warrants further investigation.

Management appears to be actively paying down borrowings, which is constructive given the D/E ratio spiked to 1.11 in 2026Q3 when equity was depressed by impairments. However, the current D/E of 0.49 partially masks the leverage picture: the ratio's improvement is partly mechanical, driven by equity recovery from $798.2M to $1.4B rather than solely by debt reduction. With operating margins hovering around 5-6% and no dividends being paid, the company is directing free cash flow toward debt repayment, which is the correct posture—but this constrains flexibility for strategic acquisitions or capital returns. Investors should monitor whether debt reduction continues or plateaus as operating cash flow normalizes.

The asset mix confirms the company's outsourced, asset-light model: PPE has declined from $382.1M in 2026Q3 to a reported $0 in 2027Q2, which may reflect a reclassification or data anomaly that warrants verification against the full financial statements. The more material concern is that $472.3M of remaining goodwill still sits against a business generating roughly $1.8B in revenue—meaning additional write-downs remain possible if any segment underperforms. The prior analysis identified that the licensed brand portfolio (Honeywell, Braun, Vicks) introduces renewal risk to the intangible base; a failure to renew or unfavorable renegotiation could trigger another impairment cycle similar to what occurred in early 2026.

The retained earnings trajectory tells the story of an acquisition strategy that required a painful reset. The $887M erosion in retained earnings between 2025Q4 and 2026Q4 dwarfs the company's annual operating income, confirming that non-cash charges rather than operating deterioration drove the equity impairment. The modest $40M recovery in retained earnings over 2027Q1-Q2 aligns with the return to positive net income noted in prior analysis, suggesting the core business may be stabilizing. However, the equity base at $1.4B is now materially thinner than at its peak, meaning any future impairment could push the company closer to its leverage covenants more quickly than in the prior cycle.

The persistently minimal cash position appears intentional rather than distress-driven, consistent with a company that likely relies on revolving credit facilities for working capital flexibility. However, the combination of only $22.6M in cash against $672.6M in total debt means the company has virtually no uncommitted liquidity buffer outside its credit lines. The current ratio of 1.65, while above 1.0, has deteriorated from its 2.00 peak in 2025Q4, and the absence of deferred revenue (consistently $0) means there is no advance-cash dynamic supporting near-term obligations. In a scenario where retailers accelerate destocking—as flagged in the business drivers analysis—working capital could tighten further and increase reliance on external financing.